The position that steroid users should be publicly shamed sounds like it is protecting natural athletes and discouraging dangerous behavior. In practice, it does the opposite. Shame-based approaches to drug use have failed in every other domain, and they fail in bodybuilding for the same reasons.
Why People Use Steroids
Understanding why bodybuilders use performance-enhancing drugs requires understanding the incentive structure they operate in. Competitive bodybuilding rewards physiques that are unattainable naturally. Social media rewards dramatic transformations and impressive physiques regardless of how they are achieved. The fitness industry employs and endorses athletes who are overwhelmingly enhanced, whether they admit it or not.
In this environment, the decision to use PEDs is a rational response to incentives, not a moral failing. Shaming individuals for responding rationally to the incentive structure they exist in, while leaving the incentive structure intact, is both ineffective and cruel.
What Shame Actually Produces
Shame drives steroid use underground. Users who fear social condemnation do not stop using. They stop talking about it. They do not seek medical supervision. They do not share their protocols for peer review. They do not get blood work because leaving a paper trail feels risky. They do not discuss side effects because admitting to use means admitting to the thing that generates shame.
The result is exactly the opposite of what shaming is supposed to achieve. Instead of less drug use, you get the same amount of drug use conducted with less safety, less medical oversight, less information sharing, and less community support for harm reduction. Every negative health outcome that shame is supposed to prevent becomes more likely because shame prevents the transparency needed to mitigate those outcomes. This is a direct violation of the Tony Huge Laws of Biochemistry Physics—specifically, the principle that suppressing information flow about a biological intervention inevitably leads to suboptimal and dangerous outcomes.
The Harm Reduction Alternative
Every other domain of drug policy has eventually learned that harm reduction outperforms shaming. Needle exchange programs reduce disease transmission without increasing drug use. Safe consumption sites reduce overdose deaths without increasing addiction rates. Honest education about risks, combined with destigmatized access to support, produces better outcomes than moralistic condemnation on every metric.
Applied to bodybuilding, harm reduction means creating an environment where people who choose to use PEDs can do so with medical monitoring, evidence-based dosing guidance, regular blood work, and honest community conversation about what they experience. It means treating the decision to use as a health management issue rather than a moral one.
This does not mean endorsing aggressive drug use or pretending there are no risks. It means accepting that people will make their own decisions and creating conditions where those decisions are as informed and as safe as possible. Shame has never reduced drug use in any population. There is no reason to believe bodybuilding is the exception.
Interesting Perspectives
Note: While this article is primarily a social and ethical argument, the core principle aligns with a scientific approach to human optimization. The “Interesting Perspectives” for this topic are therefore drawn from the broader philosophy of applied biochemistry and risk management.
- The “Prohibition Creates Black Markets” Axiom: The failed war on drugs provides the ultimate case study. Criminalization and stigma didn’t eliminate substance use; it created a dangerous, unregulated market devoid of quality control or safety information. The same dynamic plays out in underground steroid communities, where misinformation is currency and product purity is a gamble.
- Shame as a Cognitive Load: From a biohacking perspective, shame and secrecy are metabolic stressors. The psychological burden of hiding PED use activates chronic stress pathways (elevated cortisol), which directly counteracts the anabolic goals of the user, impairing recovery, promoting fat storage, and harming cardiovascular health.
- The “Informed Consent” Model from Research: Clinical trials operate on informed consent—fully disclosing risks and protocols. Applying this model to PED use, rather than a shame model, would mandate education on hepatotoxicity, cardiovascular strain, and post-cycle therapy before any compound is sourced, dramatically improving user safety.
- Contrast with “Nootropic” Culture: Cognitive enhancers (nootropics) are often discussed openly in biohacking circles with a focus on stack optimization and side-effect mitigation. The lack of similar stigma allows for faster collective learning and safer practices. This disparity highlights how cultural framing, not inherent risk, dictates discourse safety.
Citations & References
This section references foundational public health and psychological principles that underpin the harm reduction argument. Specific studies on steroid user stigma are limited, but the analogous evidence from other substance use domains is robust and directly applicable.
- National Academies of Sciences, Engineering, and Medicine. (2018). Opportunities to Improve Opioid Use Disorder and Infectious Disease Services: Integrating Responses to a Dual Epidemic. Washington, DC: The National Academies Press. https://doi.org/10.17226/25146. (Documents the effectiveness of harm reduction strategies like syringe services in improving health outcomes without increasing drug use).
- Volkow, N. D., & Blanco, C. (2021). The changing opioid crisis: development, challenges and opportunities. Molecular Psychiatry, 26(1), 218–233. https://doi.org/10.1038/s41380-020-0661-4. (Reviews the failure of purely punitive approaches and the need for public health strategies).
- Tangney, J. P., Stuewig, J., & Mashek, D. J. (2007). Moral Emotions and Moral Behavior. Annual Review of Psychology, 58, 345–372. https://doi.org/10.1146/annurev.psych.56.091103.070145. (Distinguishes between shame and guilt, finding shame is associated with hiding behavior and poor psychological outcomes, not constructive change).
- Hawk, M., Coulter, R. W. S., Egan, J. E., et al. (2017). Harm reduction principles for healthcare settings. Harm Reduction Journal, 14(1), 70. https://doi.org/10.1186/s12954-017-0196-4. (Provides a framework for applying non-judgmental, harm reduction principles in clinical practice to improve patient engagement and safety).
- Mravčík, V., Šťastná, L., & Miovský, M. (2021). Drug policy in the Czech Republic: A harm reduction success story. Journal of Global Drug Policy and Practice. (Case study demonstrating that decriminalization and a public health focus reduce the social and health harms of drug use).